Search

Various forms of expressive arts are known to have associations with positive academic, social, and behavioral outcomes in addition to offering important therapeutic benefits for children and adolescents. However, very limited knowledge has been developed regarding specific expressive arts interventions for promoting positive youth development and preventing problematic behaviors in youth from urban, low socioeconomic neighborhoods. Therefore, the purpose of the current study was to expand the nascent research area in arts interventions by evaluating an expressive art intervention offered to youth through a positive youth development program located in several public housing neighborhoods. Quasi-experimental design was applied to test the impact of a poetry-focused art intervention on self-reported perceptions of academics, social competence, and multicultural attitudes of a culturally diverse sample of 40 urban sixth to eighth grade youth. Participants were recruited through a positive youth development program located in the public housing neighborhoods where they reside. Pre and post data were collected. Prior to the arts intervention, there were no statistically significant differences between the youth on self-report measures of academic capacity and social competence. The first group of youth who participated in the intervention reported enhanced capacity on all three measures when compared to peers who had not yet participated in the program. However, the second group of youth to receive the program showed no statistically significant gains when compared to their peers who received the intervention first. The study provides compelling support to further explore the efficacy of expressive arts on influencing attributes of positive youth development among urban adolescents. In addition, the study offers valuable insights into the process and complexities involved in developing agency partnerships and conducting research on after-school programs. [ABSTRACT FROM AUTHOR]

Patients with advanced solid malignancies were enrolled to an open-label, single-arm, dose-escalation study, in which CRLX101 was administered intravenously over 60 min among two dosing schedules, initially weekly at 6, 12, and 18 mg/m and later bi-weekly at 12, 15, and 18 mg/m. The maximum tolerated dose (MTD) was determined at 15 mg/m bi-weekly, and an expansion phase 2a study was completed. Patient samples were obtained for pharmacokinetic (PK) and pharmacodynamic (PD) assessments. Response was evaluated per RECIST criteria v1.0 every 8 weeks. Sixty-two patients (31 male; median age 63 years, range 39-79) received treatment. Bi-weekly dosing was generally well tolerated with myelosuppression being the dose-limiting toxicity. Among all phase 1/2a patients receiving the MTD ( n = 44), most common grade 3/4 adverse events were neutropenia and fatigue. Evidence of systemic plasma exposure to both the polymer-conjugated and unconjugated CPT was observed in all treated patients. Mean elimination unconjugated CPT T values ranged from 17.7 to 24.5 h, and maximum plasma concentrations and areas under the curve were generally proportional to dose for both polymer-conjugated and unconjugated CPT. Best overall response was stable disease in 28 patients (64 %) treated at the MTD and 16 (73 %) of a subset of NSCLC patients. Median progression-free survival (PFS) for patients treated at the MTD was 3.7 months and for the subset of NSCLC patients was 4.4 months. These combined phase 1/2a data demonstrate encouraging safety, pharmacokinetic, and efficacy results. Multinational phase 2 clinical development of CRLX101 across multiple tumor types is ongoing. [ABSTRACT FROM AUTHOR]